Sfoglia per Autore
GAMMA-DELTA T-LYMPHOCYTE SPECIFIC CLONES ARE INVOLVED IN THE GRAFT-VERSUS-MYELOMA AND IN THE GRAFT-VERSUS-HOST DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER NON-MYELOABLATIVE TRANSPLANTATION.
2005-01-01 Galimberti, Sara; Benedetti, E; Morabito, F; Battolla, B; Petrini, Iacopo; Papineschi, Federico; Martino, M; Console, G; Iacopino, P; Petrini, Mario
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.)
2006-01-01 Bursi, S.; Masi, G.; Antonuzzo, A.; Cerri, E.; Loupakis, F.; Barbara, C.; Barletta, M.; Allegrini, G.; Cupini, S.; Ricci, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; Murr, R.; Petrini, Iacopo; Tognarini, L.; Andreuccetti, M.; Falcone, Alfredo
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation
2006-01-01 Galimberti, Sara; Benedetti, E; Morabito, F; Petrini, Iacopo; Battolla, B; Papineschi, Federico; Fazzi, R; Ciabatti, Elena; Martino, M; Cuzzola, M; Console, G; Iacopino, P; Petrini, Mario
Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells
2007-01-01 Petrini, Iacopo; Fazzi, R; Pacini, Simone; Galimberti, Sara; Trombi, Luisa; Ciabatti, Elena; Petrini, Mario
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
2007-01-01 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Barletta, M. T.; Baldi, G. G.; Vasile, E.; Fornaro, L.; Petrini, Iacopo; Allegrini, G.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
HUMAN MESENCHYMAL CELLS INHIBIT IL2 AND ZOLEDRONATE-INDUCED GAMMA/DELTA T-CELLS.
2007-01-01 Petrini, Iacopo; Fazzi, R; Pacini, S; Galimberti, Sara; Trombi, L; Ciabetti, E; Petrini, Mario
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Baldi, G.; Antonuzzo, A.; Sonaglio, C.; Pfanner, E.; Petrini, Iacopo; Falcone, Alfredo
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G.; Barletta, M.; Allegrini, G.; Ricci, S.; Falcone, Alfredo
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES
2007-01-01 Fazzi, R; Pacini, S; Petrini, Iacopo; Galimberti, Sara; Trombi, L; Ciabatti, E; Petrini, Mario
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Masi, G.; Baldi, G.; Fornaio, L.; Schiavon, G.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Funel, N.; Campani, Daniela; Tonini, G.; Cascinu, S.; Falcone, Alfredo
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
2008-01-01 Masi, G.; Vasile, E.; Loupakis, F.; Bursi, S.; Ricci, S.; Petrini, Iacopo; Fontana, A.; Allegrini, G.; Falcone, Alfredo
Array Comparative Genomic Hybridization analysis of resected thymomas on paraffin embedded material
2009-01-01 Petrini, Iacopo; Zuccali, P. A; Meltzer, P; Killian, K; Di Tommaso, L; Incarbone, M; Suuriniemi, M; Merino, M; Wang, Y; Santoro, A; Giaccone, G.
Reproducibility of the WHO classification for thymomas in relation to prognosis
2009-01-01 Petrini, Iacopo; Lee, Hs; Di Tommaso, L; Merino, M; Zucali, P. A; Incarbone, M; Santoro, A; Giaccone, G.
WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS (NETS): ANALYSIS OF 86 CASES TREATED WITH LONG ACTING SOMATOSTATINE ANALOGUES (SSA)
2009-01-01 Iannopollo, Mauro; Ricasoli, Miriam; Petrini, Iacopo; Lencioni, Monica; Orlandini, Cinzia; Ricci, Sergio
A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data.
2009-01-01 Petrini, Iacopo; Lencioni, M; Ricasoli, M; Iannopollo, M; Orlandini, C; Oliveri, F; Filipponi, Franco; Bartolozzi, Carlo; DEL TACCA, Mario; Ricci, S.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| GAMMA-DELTA T-LYMPHOCYTE SPECIFIC CLONES ARE INVOLVED IN THE GRAFT-VERSUS-MYELOMA AND IN THE GRAFT-VERSUS-HOST DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER NON-MYELOABLATIVE TRANSPLANTATION. | 1-gen-2005 | Galimberti, Sara; Benedetti, E; Morabito, F; Battolla, B; Petrini, Iacopo; Papineschi, Federico; Martino, M; Console, G; Iacopino, P; Petrini, Mario | |
| Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2006 | Bursi, S.; Masi, G.; Antonuzzo, A.; Cerri, E.; Loupakis, F.; Barbara, C.; Barletta, M.; Allegrini, G.; Cupini, S.; Ricci, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; Murr, R.; Petrini, Iacopo; Tognarini, L.; Andreuccetti, M.; Falcone, Alfredo | |
| Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation | 1-gen-2006 | Galimberti, Sara; Benedetti, E; Morabito, F; Petrini, Iacopo; Battolla, B; Papineschi, Federico; Fazzi, R; Ciabatti, Elena; Martino, M; Cuzzola, M; Console, G; Iacopino, P; Petrini, Mario | |
| Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells | 1-gen-2007 | Petrini, Iacopo; Fazzi, R; Pacini, Simone; Galimberti, Sara; Trombi, Luisa; Ciabatti, Elena; Petrini, Mario | |
| Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) | 1-gen-2007 | Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Barletta, M. T.; Baldi, G. G.; Vasile, E.; Fornaro, L.; Petrini, Iacopo; Allegrini, G.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo | |
| HUMAN MESENCHYMAL CELLS INHIBIT IL2 AND ZOLEDRONATE-INDUCED GAMMA/DELTA T-CELLS. | 1-gen-2007 | Petrini, Iacopo; Fazzi, R; Pacini, S; Galimberti, Sara; Trombi, L; Ciabetti, E; Petrini, Mario | |
| Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo | |
| The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) | 1-gen-2007 | Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Baldi, G.; Antonuzzo, A.; Sonaglio, C.; Pfanner, E.; Petrini, Iacopo; Falcone, Alfredo | |
| First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G.; Barletta, M.; Allegrini, G.; Ricci, S.; Falcone, Alfredo | |
| First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo | |
| MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES | 1-gen-2007 | Fazzi, R; Pacini, S; Petrini, Iacopo; Galimberti, Sara; Trombi, L; Ciabatti, E; Petrini, Mario | |
| Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Masi, G.; Baldi, G.; Fornaio, L.; Schiavon, G.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Funel, N.; Campani, Daniela; Tonini, G.; Cascinu, S.; Falcone, Alfredo | |
| Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo | |
| Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo | |
| Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
| Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer | 1-gen-2008 | Masi, G.; Vasile, E.; Loupakis, F.; Bursi, S.; Ricci, S.; Petrini, Iacopo; Fontana, A.; Allegrini, G.; Falcone, Alfredo | |
| Array Comparative Genomic Hybridization analysis of resected thymomas on paraffin embedded material | 1-gen-2009 | Petrini, Iacopo; Zuccali, P. A; Meltzer, P; Killian, K; Di Tommaso, L; Incarbone, M; Suuriniemi, M; Merino, M; Wang, Y; Santoro, A; Giaccone, G. | |
| Reproducibility of the WHO classification for thymomas in relation to prognosis | 1-gen-2009 | Petrini, Iacopo; Lee, Hs; Di Tommaso, L; Merino, M; Zucali, P. A; Incarbone, M; Santoro, A; Giaccone, G. | |
| WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS (NETS): ANALYSIS OF 86 CASES TREATED WITH LONG ACTING SOMATOSTATINE ANALOGUES (SSA) | 1-gen-2009 | Iannopollo, Mauro; Ricasoli, Miriam; Petrini, Iacopo; Lencioni, Monica; Orlandini, Cinzia; Ricci, Sergio | |
| A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. | 1-gen-2009 | Petrini, Iacopo; Lencioni, M; Ricasoli, M; Iannopollo, M; Orlandini, C; Oliveri, F; Filipponi, Franco; Bartolozzi, Carlo; DEL TACCA, Mario; Ricci, S. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile